Treats metastatic carcinoid tumors. ANDA 79198, held by Mylan Institutional. Octreotide Acetate.
As of Nov 16, 2026, ANDA 79198 (Octreotide Acetate (Preservative Free)), held by Mylan Institutional, was first approved by FDA on Feb 10, 2011, with 9 approved supplements and 0 published complete response letters.
Octreotide acetate injection is a somatostatin analogue indicated:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 10, 2011 | Original application | Approved | None posted |
| Octreotide Acetate (Preservative Free)EQ 0.05MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Octreotide Acetate (Preservative Free)EQ 0.1MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Octreotide Acetate (Preservative Free)EQ 0.5MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Feb 21, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Feb 21, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Feb 21, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 5, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 7, 2017 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 7, 2017 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 23, 2013 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 2, 2011 | Supplement 2Labeling | Approved | None posted |
| Jul 14, 2011 | Supplement 1Labeling | Approved | None posted |
| Feb 10, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters